Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center

Ixekizumab (Taltz(®)) is a humanized anti-IL-17A monoclonal antibody approved for the treatment of various inflammatory diseases including psoriasis and psoriatic arthritis. Despite the favorable efficacy and safety, ixekizumab is also known for its high incidence of injection site reactions (ISRs),...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, I-Heng, Tsai, Tsen-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296553/
https://www.ncbi.nlm.nih.gov/pubmed/37371813
http://dx.doi.org/10.3390/biomedicines11061718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296553/
https://www.ncbi.nlm.nih.gov/pubmed/37371813
http://dx.doi.org/10.3390/biomedicines11061718

Ejemplares similares